Enovis (NYSE:ENOV) Trading Down 6.4% – What’s Next?

Enovis Corporation (NYSE:ENOV) fell 6.4% on Tuesday . The stock traded as low as $22.87 and last traded at $23.0210. 184,825 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 1,071,094 shares. The stock had previously closed at $24.59.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: The acquisition would expand Enovis’ ASTRA enabling-technology platform into orthopedic surgical robotics, adding robotic automation, imaging and navigation capabilities. Management expects the combination to improve surgical precision and workflow efficiency while creating a broader platform for future growth. Enovis acquisition announcement
• Positive Sentiment: Wells Fargo lowered its Enovis price target to $33 from $39 but maintained an “overweight” rating. Citizens JMP also reduced its target, to $47 from $55, while retaining a “market outperform” rating. The continued positive ratings indicate analysts see substantial long-term upside despite near-term concerns.
• Neutral Sentiment: Enovis plans to pay approximately €155 million, or about $180 million, for eCential Robotics. The transaction is intended to bring eCential’s surgical robot to market and broaden Enovis’ orthopedic technology portfolio. Enovis to acquire eCential Robotics for €155 million
• Negative Sentiment: Investors reacted negatively because the deal is expected to pressure Enovis’ margins in 2027. The acquisition also introduces execution, commercialization and integration risks as the company invests in developing and scaling the surgical robotics business. Shares have declined sharply following the announcement. Enovis drops after eCential acquisition offer

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Evercore set a $32.00 price objective on Enovis in a research note on Monday, July 6th. Canaccord Genuity Group lowered their target price on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. UBS Group restated a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Finally, Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.38.

Enovis Stock Performance

The company’s 50-day moving average price is $25.63 and its two-hundred day moving average price is $24.26. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -1.05 and a beta of 1.31. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. Enovis’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts anticipate that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased 3,200 shares of company stock valued at $69,864 in the last ninety days. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First National Bank of Omaha bought a new stake in shares of Enovis during the second quarter valued at approximately $1,250,000. Front Street Capital Management Inc. increased its stake in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares in the last quarter. Bernzott Capital Advisors lifted its stake in shares of Enovis by 47.4% in the first quarter. Bernzott Capital Advisors now owns 294,125 shares of the company’s stock valued at $6,691,000 after buying an additional 94,529 shares in the last quarter. Invenomic Capital Management LP grew its holdings in shares of Enovis by 6.2% during the fourth quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock valued at $20,159,000 after buying an additional 44,048 shares during the last quarter. Finally, Great Lakes Advisors LLC acquired a new stake in shares of Enovis in the 2nd quarter worth about $1,588,000. 98.45% of the stock is owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.